At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 119 enrolled
Drug / intervention
PQ Grass +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled Exploratory Study to Explore the Efficacy and Safety of PQ Grass 27600 SU in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Exposure
In Brief
A Phase 3 clinical trial evaluating PQ Grass, Active Placebo, and 1 other intervention for Rhinitis, Allergic, Seasonal. Completed, enrolled 119 participants across 14 sites in 2 countries.
Detailed Summary
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
CountriesGermany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedDec 2020
Primary CompletionAug 2021
Study CompletionOct 2021
TodayJul 2026
First PostedDec 29, 2020
Enrollment StartOct 19, 2020
Primary CompletionAug 18, 2021
Study CompletionOct 28, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.5 years ago
Interventions
PQ Grassbiological
Suspension for injection
Active Placebodrug
Suspension for injection
Standard Placebodrug
Solution for injection